<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934933</url>
  </required_header>
  <id_info>
    <org_study_id>[2013]2-93</org_study_id>
    <nct_id>NCT01934933</nct_id>
  </id_info>
  <brief_title>Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis</brief_title>
  <official_title>A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open label, randomized clinical trial of etanercept and celecoxib
      alone/combined treatment in effectiveness and safety on active ankylosing spondylitis (AS).
      Subjects will be randomly assigned in a 1:1:1 ratio to one of the three groups (celexocib
      200mg bid, etanercept 50mg qw, etanercept plus Celecoxib group) for 54 weeks. Primary
      endpoints are the magnetic resonance imaging (MRI) Spondyloarthritis Research Consortium of
      Canada (SPARCC) score of sacroiliac(SI) joint and spine, as well as the Assessment of
      SpondyloArthritis International Society (ASAS)20 response rate at 52 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, open label, randomized clinical trial evaluating the effectiveness and safety
      of etanercept and celecoxib alone/combined treatment will be conducted on active ankylosing
      spondylitis (AS) patients. Disease activity is defined as fulfilling three aspects below:
      BASDAI ≥ 4 or ASDAS≥ 2.1；CRP＞6 mg/L or ESR 28 mm/1st hour；more than 2 and less than 16
      syndesmophyts between cervical spine and lumber spine detected by X-ray. All patients were
      randomly assigned in a 1:1:1 ratio to one of the three treatment groups：celecoxib 200mg
      bid，etanercept 50mg qw and combined therapy for 52 weeks. Primary endpoints are the magnetic
      resonance imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) score of
      sacroiliac(SI) joint and spine, as well as the Assessment of SpondyloArthritis International
      Society (ASAS) 20 response rate at 52 weeks. Key secondary Endpoints include the modified
      Stoke Ankylosing Spondylitis Spine Score (mSASSS), Spondyloarthritis Research Consortium of
      Canada (SPRACC) SI joint structural score (SSS), BASDAI, ASDAS, ASAS40, ASAS70 and ASAS5/6
      response rate at 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2014</start_date>
  <completion_date type="Actual">January 30, 2017</completion_date>
  <primary_completion_date type="Actual">September 23, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the SPARCC score of spine and SI joint</measure>
    <time_frame>52th weeks</time_frame>
    <description>the MRI SPARCC score of spine and SI joint on 52th week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ASAS20 response rate</measure>
    <time_frame>52th week</time_frame>
    <description>ASAS20 response rate on 52th week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASAS40 response rate</measure>
    <time_frame>52th week</time_frame>
    <description>ASAS40 response rate on 52th week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS70 response</measure>
    <time_frame>52th week</time_frame>
    <description>ASAS70 response rate on 52th week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASDAS</measure>
    <time_frame>52th week</time_frame>
    <description>ASDAS major improvement ASDAS clinically important improvement on 52th week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mSASSS score of spine</measure>
    <time_frame>52th week</time_frame>
    <description>the mSASSS score of spine on 52th week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spondyloarthritis Research Consortium of Canada (SPRACC) SI joint structural score (SSS)</measure>
    <time_frame>52th week</time_frame>
    <description>the MRI SPARCC SSS score of spine on 52th week</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>celebrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>celebrex capsule, 0.2 gram bid, 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enbrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etanercept injection, 25mg per injection, 50mg/week, 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enbrel plus Celebrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg/week Enbrel by hypodermic injection plus Celebrex 0.2 gram bid, 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celebrex</intervention_name>
    <arm_group_label>celebrex</arm_group_label>
    <other_name>celecoxib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel</intervention_name>
    <arm_group_label>Enbrel</arm_group_label>
    <other_name>etanercept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel plus Celebrex</intervention_name>
    <arm_group_label>Enbrel plus Celebrex</arm_group_label>
    <other_name>celecoxib plus etanercept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years

          -  Meet 1984 NewYork modified criteria for AS

          -  BASDAI≥4 or ASDAS score ≥ 2.1

          -  CRP＞6 mg/L or ESR＞28 mm/h

          -  Syndesmophyte quantity ≥2 and ＜16 of spine

          -  Sexually active women of childbearing potential must agree and commit to use a
             medically accepted form of contraception

          -  No active or latent tuberculosis infection.

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  current or previous history of psoriasis or inflammatory bowel disease.

          -  infection with clinical significance within 24 weeks before screening

          -  receipt any bio-agents treatment within 12 weeks before screening

          -  corticosteroids intra-articular injections in last 3 months before the trial

          -  Significant concurrent medical events including: Gastrointestinal ulcer, myocardial
             infarction within 12 months before the screening visit, unstable angina pectoris,
             congestive heart failure.

          -  Alcohol and drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jieruo Gu, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Department of Rheumatology ,Third Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Department, the Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>August 17, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>June 14, 2018</last_update_submitted>
  <last_update_submitted_qc>June 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Gu Jieruo</investigator_full_name>
    <investigator_title>Department of Rheumatology, Third Affiliated Hospital of Sun Yat-sen University</investigator_title>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>etanercept</keyword>
  <keyword>celecoxib</keyword>
  <keyword>ankylsoing spondylitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

